Regeneron Pharmaceuticals (REGN) Assets Average (2010 - 2026)

Regeneron Pharmaceuticals' Assets Average history runs 17 years deep, the most recent figure standing at $40.7 billion for Q1 2026.

• In Q1 2026, Assets Average rose 8.13% year-over-year to $40.7 billion; the TTM figure through Mar 2026 stood at $40.7 billion (up 8.13% YoY), while the FY2025 annual figure was $39.2 billion, up 10.56% from the prior year.
• Assets Average was $40.7 billion for Q1 2026 at Regeneron Pharmaceuticals, up from $40.4 billion in the prior quarter.
• In the past five years, Assets Average ranged from a high of $40.7 billion in Q1 2026 to a low of $25.9 billion in Q1 2022.
• Historically, Assets Average has averaged $33.6 billion across 5 years, with a median of $33.7 billion in 2024.
• The sharpest annual moves came in 2022 and 2025: Assets Average soared 48.23% in 2022, then increased 6.61% in 2025.
• A 5-year view of Assets Average shows it stood at $28.4 billion in 2022, then climbed by 14.68% to $32.6 billion in 2023, then increased by 15.26% to $37.6 billion in 2024, then gained by 7.35% to $40.4 billion in 2025, then rose by 0.87% to $40.7 billion in 2026.
• The last three Assets Average figures came in at $40.7 billion (Q1 2026), $40.4 billion (Q4 2025), and $39.2 billion (Q3 2025), per Business Quant data.